Terms: = Prostate cancer AND NCOA2, TIF2, 10499, ENSG00000140396, NCoA-2, MGC138808 AND Treatment
16 results:
1. Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening.
Haldrup J; Weiss S; Schmidt L; Sørensen KD
Sci Rep; 2023 Jun; 13(1):9043. PubMed ID: 37270558
[TBL] [Abstract] [Full Text] [Related]
2. Qingdai Decoction suppresses prostate cancer growth in lethal-stage prostate cancer models.
Chen Y; Zhou Q; Zhang H; Xu L; Lu L; Shu B; Zhou L; Yuan F
J Ethnopharmacol; 2023 May; 308():116333. PubMed ID: 36863640
[TBL] [Abstract] [Full Text] [Related]
3. African-specific molecular taxonomy of prostate cancer.
Jaratlerdsiri W; Jiang J; Gong T; Patrick SM; Willet C; Chew T; Lyons RJ; Haynes AM; Pasqualim G; Louw M; Kench JG; Campbell R; Horvath LG; Chan EKF; Wedge DC; Sadsad R; Brum IS; Mutambirwa SBA; Stricker PD; Bornman MSR; Hayes VM
Nature; 2022 Sep; 609(7927):552-559. PubMed ID: 36045292
[TBL] [Abstract] [Full Text] [Related]
4. Independent prognostic impact of plasma ncoa2 alterations in metastatic castration-resistant prostate cancer.
Fettke H; Kwan EM; Bukczynska P; Steen JA; Docanto M; Ng N; Parente P; Mant A; Foroughi S; Pezaro C; Hauser C; Nguyen-Dumont T; Southey MC; Azad AA
Prostate; 2021 Sep; 81(13):992-1001. PubMed ID: 34254334
[TBL] [Abstract] [Full Text] [Related]
5. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the treatment of prostate cancer.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
[TBL] [Abstract] [Full Text] [Related]
6. High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
Hua Y; Shun TY; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2014 Sep; 12(7):395-418. PubMed ID: 25181412
[TBL] [Abstract] [Full Text] [Related]
7. prostate cancer genomic signature offers prognostic value.
Troutman SM; Price DK; Figg WD
Cancer Biol Ther; 2010 Dec; 10(11):1079-80. PubMed ID: 21088497
[TBL] [Abstract] [Full Text] [Related]
8. Integrative genomic profiling of human prostate cancer.
Taylor BS; Schultz N; Hieronymus H; Gopalan A; Xiao Y; Carver BS; Arora VK; Kaushik P; Cerami E; Reva B; Antipin Y; Mitsiades N; Landers T; Dolgalev I; Major JE; Wilson M; Socci ND; Lash AE; Heguy A; Eastham JA; Scher HI; Reuter VE; Scardino PT; Sander C; Sawyers CL; Gerald WL
Cancer Cell; 2010 Jul; 18(1):11-22. PubMed ID: 20579941
[TBL] [Abstract] [Full Text] [Related]
9. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via tif2.
Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC
Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160
[TBL] [Abstract] [Full Text] [Related]
10. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor.
Haelens A; Tanner T; Denayer S; Callewaert L; Claessens F
Cancer Res; 2007 May; 67(9):4514-23. PubMed ID: 17483368
[TBL] [Abstract] [Full Text] [Related]
11. prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract] [Full Text] [Related]
12. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract] [Full Text] [Related]
13. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract] [Full Text] [Related]
14. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.
Culig Z; Steiner H; Bartsch G; Hobisch A
Endocr Relat Cancer; 2005 Jun; 12(2):229-44. PubMed ID: 15947099
[TBL] [Abstract] [Full Text] [Related]
15. Androgen receptors in prostate cancer.
Culig Z; Klocker H; Bartsch G; Hobisch A
Endocr Relat Cancer; 2002 Sep; 9(3):155-70. PubMed ID: 12237244
[TBL] [Abstract] [Full Text] [Related]
16. Different expression of androgen receptor coactivators in human prostate.
Fujimoto N; Mizokami A; Harada S; Matsumoto T
Urology; 2001 Aug; 58(2):289-94. PubMed ID: 11489729
[TBL] [Abstract] [Full Text] [Related]
